{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:23:51Z","timestamp":1772033031419,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T00:00:00Z","timestamp":1399939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1245\/s10434-014-3693-7","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T20:40:12Z","timestamp":1399927212000},"page":"3621-3627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study"],"prefix":"10.1245","volume":"21","author":[{"given":"Jean-Fran\u00e7ois","family":"Le Brun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Campion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Berton-Rigaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Lorimier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenael","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Sophie","family":"Oger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Dravet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Jaffre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Classe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,13]]},"reference":[{"key":"3693_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1684\/bdc.2008.0795","volume":"96","author":"S Guerin","year":"2009","unstructured":"Guerin S, Doyon F, Hill C. [The frequency of cancer in France in 2006, mortality trends since 1950, incidence trends since 1980 and analysis of the discrepancies between these trends]. Bull Cancer. 2009;96:51\u20137.","journal-title":"Bull Cancer"},{"key":"3693_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2004.07.033","volume":"95","author":"MM Leitao Jr","year":"2004","unstructured":"Leitao MM, Jr., Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2004;95:181\u20138.","journal-title":"Gynecol Oncol"},{"key":"3693_CR3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet. 2003; 361: 2099\u2013106.","journal-title":"Lancet"},{"key":"3693_CR4","unstructured":"Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983;61:189\u201393."},{"key":"3693_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265\u201374.","journal-title":"Gynecol Oncol"},{"key":"3693_CR6","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702\u201310.","journal-title":"Ann Surg Oncol"},{"key":"3693_CR7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ejso.2011.08.138","volume":"37","author":"JM Classe","year":"2011","unstructured":"Classe JM, Jaffre I, Frenel JS, et al. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases. Eur J Surg Oncol. 2011;37:971\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"3693_CR8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2008.08.027","volume":"112","author":"MJ Fulham","year":"2009","unstructured":"Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol. 2009;112:462\u20138.","journal-title":"Gynecol Oncol"},{"key":"3693_CR9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/IGC.0b013e318234f833","volume":"22","author":"ME Skaznik-Wikiel","year":"2012","unstructured":"Skaznik-Wikiel ME, Lesnock JL, McBee WC, et al. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. Int J Gynecol Cancer. 2012;22:232\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"3693_CR10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med"},{"key":"3693_CR11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.soc.2012.07.007","volume":"21","author":"CW Helm","year":"2012","unstructured":"Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 2012;21:645\u201363.","journal-title":"Surg Oncol Clin N Am"},{"key":"3693_CR12","first-page":"256","volume":"40","author":"JS Spratt","year":"1980","unstructured":"Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256\u201360.","journal-title":"Cancer Res"},{"key":"3693_CR13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00685503","volume":"28","author":"G Los","year":"1991","unstructured":"Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159\u201365.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3693_CR14","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900\u20137.","journal-title":"Ann Surg"},{"key":"3693_CR15","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.2174\/138161212802002616","volume":"18","author":"S Mulier","year":"2012","unstructured":"Mulier S, Claes JP, Dierieck V, et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18:3793\u2013803.","journal-title":"Curr Pharm Des"},{"issue":"Suppl","key":"3693_CR16","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s002800051093","volume":"43","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43 Suppl:S15\u201325.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3693_CR17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12094-009-0438-3","volume":"11","author":"FC Munoz-Casares","year":"2009","unstructured":"Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753\u20139.","journal-title":"Clin Transl Oncol"},{"key":"3693_CR18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127:502\u20135.","journal-title":"Gynecol Oncol"},{"key":"3693_CR19","first-page":"74","volume":"16","author":"J Spiliotis","year":"2011","unstructured":"Spiliotis J, Vaxevanidou A, Sergouniotis F, et al. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J Buon. 2011;16:74\u20139.","journal-title":"J Buon"},{"key":"3693_CR20","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","volume":"25","author":"WE Winter 3rd","year":"2007","unstructured":"Winter WE, 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621\u20137.","journal-title":"J Clin Oncol"},{"key":"3693_CR21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933\u20139.","journal-title":"Cancer"},{"key":"3693_CR22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000159266","volume":"75","author":"A Fagotti","year":"2008","unstructured":"Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET\/CT and staging laparoscopy. Oncology. 2008;75:152\u20138.","journal-title":"Oncology"},{"key":"3693_CR23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11912-003-0004-z","volume":"5","author":"G Friberg","year":"2003","unstructured":"Friberg G, Fleming G. Intraperitoneal chemotherapy for ovarian cancer. Curr Oncol Rep. 2003;5:447\u201353.","journal-title":"Curr Oncol Rep"},{"key":"3693_CR24","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","volume":"135","author":"TC Chua","year":"2009","unstructured":"Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3693_CR25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2008.12.022","volume":"113","author":"M Markman","year":"2009","unstructured":"Markman M. Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation. Gynecol Oncol. 2009;113:4\u20135.","journal-title":"Gynecol Oncol"},{"key":"3693_CR26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-2003-44484","volume":"125","author":"K Chatzigeorgiou","year":"2003","unstructured":"Chatzigeorgiou K, Economou S, Chrysafis G, et al. Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol. 2003;125:424\u20139.","journal-title":"Zentralbl Gynakol"},{"key":"3693_CR27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00268-004-7461-x","volume":"28","author":"C Zanon","year":"2004","unstructured":"Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004;28:1040\u20135.","journal-title":"World J Surg"},{"key":"3693_CR28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1471-0528.2011.03207.x","volume":"119","author":"M Deraco","year":"2012","unstructured":"Deraco M, Virzi S, Iusco DR, et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012;119:800\u20139.","journal-title":"Bjog"},{"key":"3693_CR29","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-009-0878-6","volume":"19","author":"WP Ceelen","year":"2012","unstructured":"Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol. 2012;19:2352\u20139.","journal-title":"Ann Surg Oncol"},{"key":"3693_CR30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2013.01.010","volume":"129","author":"PA Argenta","year":"2013","unstructured":"Argenta PA, Sueblinvong T, Geller MA, et al. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol. 2013;129:81\u20135.","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3693-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-014-3693-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3693-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T09:20:12Z","timestamp":1597828812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-014-3693-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,13]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3693-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,13]]}}}